We hope you all took advantage of the Thanksgiving holiday to rest and relax. We did.
In Today’s NEWS
RegenxBio Offers Rocket Pharmaceuticals exclusive, worldwide, rights to adenoviral vector NAV AAV9 for the development of treatments for Danon Disease
RegenxBio (RGNX) announced that it awarded an exclusive, worldwide, license agreement to Rocket Pharmaceuticals (RCKT) so it can develop gene therapy for Danon disease. The exclusive license enables Rocket to use RegenxBio's . . .
This content is for paid subscribers.
Today’s Highlights
November 26, 2018
